Multiple Myeloma
Multiple Myeloma
We’re here for you. Call us at 844-346-7222 or
find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at (201) 518-3587, or email us at email.
33
Clinical Trials
Multiple Myeloma
Phase I/II
Accepting Patients
nct/study# NCT03732703 / MMRC-085
Myeloma-Developing Regimens Using Genomics (Mydrug) (Genomics Guided Multi-Arm Trial Of Targeted Agents Alone Or In Combination With A Backbone Regimen)
Learn More
Multiple Myeloma
Phase I
Accepting Patients
nct/study# NCT04398680 / GSK-209627
A Phase I Study to Evaluate the pharmacokinetics and safety of Belantamab Mafodotin Monotherapy in participants with Relapsed or Refractory Multiple Myeloma who have normal and varying degrees of impaired hepatic function (DREAMM 13)
Learn More
Multiple Myeloma
Phase II
Accepting Patients
nct/study# NCT04649359 / C1071003
An Open-Label, Multicenter, Non-Randomized Phase 2 Study Of Pf-06863135 Monotherapy In Participants With Multiple Myeloma Who Are Refractory To At Least One Proteasome Inhibitor, One Immunomodulatory Drug And One Anti-Cd38 Antibody
Learn More
Multiple Myeloma
Phase I
Accepting Patients
nct/study# NCT02332850 / 139511-MMRC
A Phase Ib Study Of SAR650984 (Anti-CD38 Mab) In Combination With Carfilzomib For The Treatment Of Relapsed Or Refractory Multiple Myeloma
Learn More
Multiple Myeloma
Phase III
Active
nct/study# NA / 64007957MMY3001
A Phase 3 Randomized Study Comparing Teclistamab In Combination With Daratumumab SC (Tecdara) Versus Daratumumab SC, Pomalidomide And Dexamethasone (Dpd) Or Daratumumab SC, Bortezomib, And Dexamethasone (Dvd) In Participants With Relapsed Or Refractory Multiple Myeloma
Learn More
Multiple Myeloma
NA
Active
nct/study# NA / KARYOPHARM-RWE
Treatment Patterns And Adverse Event Management In Patients Treated With Selinexor In Combination With Other Approved Agents For Relapsed/Refractory Multiple Myeloma: Real-World Evidence Based On Electronic Medical Record Data
Learn MoreWe are here for you
For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.